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OBJECTIVES: Clostridium difficile infection (CDI) repre-
sents a cause of substantial morbidity, particularly for older
adults. Although older age is a risk factor for CDI, few
studies have specifically focused on clinical outcomes in
older adults, particularly the ‘‘oldest’’ old.
DESIGN: Retrospective review.
SETTING: University of Michigan Health System.
PARTICIPANTS: All patients aged 80 and older with a
positive cytotoxin assay for C. difficile and a clinical course
consistent with CDI during 2006.
MEASUREMENTS: Clinical data were recorded, includ-
ing comorbid conditions and treatment regimens, as well as
outcomes, including treatment failure, infection relapse,
and 90-day mortality.
RESULTS: Seventy patients aged 80 and older (mean
84.0  4.1) with CDI were identified. Metronidazole was
given as initial therapy in 65 (92.8%); 18 of these 65
(27.7%) experienced treatment failure, requiring subse-
quent use of oral vancomycin. Serious adverse events in-
cluded three episodes of toxic megacolon, two requiring
colectomy. One death was directly attributable to CDI. All-
cause mortality was 8.6% at 30 days and 17.1% at 90 days.
Higher white blood cell (WBC) counts were independently
associated with treatment failure (P 5.02) and coronary
artery disease with 90-day mortality (P 5.02).
CONCLUSION: In older adults with CDI, treatment fail-
ure on metronidazole occurred frequently and was associ-
ated with higher WBC count. Larger prospective studies are
needed to determine risk factors for treatment failure and
relapse in order to develop better paradigms for CDI treat-
ment in older adults. Initial therapy with vancomycin may
be appropriate for elderly patients, especially those with
elevated WBC counts. J Am Geriatr Soc 57:659–662, 2009.
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In recent years, the incidence and severity of Clostridiumdifficile infection (CDI) have increased. With the emer-
gence of the highly toxigenic strain, BI/NAP1, CDI has
emerged as a cause of substantial morbidity and healthcare
costs, especially in older adults.1–3 In recent reports of BI/
NAP1 outbreaks, age of 65 and older has been highlighted
as an important risk factor for developing CDI, as well as
for greater disease severity and higher mortality.4–6
The Centers for Disease Control and Prevention (CDC)
reports that hospital discharge diagnosis of CDI nearly
doubled from 1996 to 2003, increasing from 31 to 61 dis-
charges per 100,000 population.5 This increase was most
notable in older adults; in persons aged 65 and older, rates
increased from approximately 150 discharges per 100,000
population in 1996 to 300 discharges per 100,000 popu-
lation in 2003. In addition to greater incidence and mor-
tality, older adults experience higher rates of treatment
failures and disease relapse.5,6
Although older age has been repeatedly identified as a
risk factor for CDI, few studies have specifically focused on
clinical outcomes of CDI in older adults. It was desired to
examine the clinical course of CDI in the ‘‘oldest’’ old
(80), including the rate of important complications, such
as need for hospitalization or surgical intervention, and
death. Treatment failure and relapse of disease within 90
days of initial treatment were also recorded.
METHODS
Setting and Population
The University of Michigan Health System (UMHS) is a
850-bed tertiary care facility. Using microbiology records,
all patients aged 80 and older cared for at the UMHS with a
positive enzyme-linked immunosorbent assay for C. difficile
cytotoxin A or B and a clinical course consistent with CDI
from January 1, 2006, to December 31, 2006, were iden-
tified. Medical records were reviewed and information of
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interest recorded including demographic data, clinical con-
ditions, and characteristics of CDI. We assessed treatment
regimens, complications (including toxic megacolon and
need for surgery), pre- and post-hospitalization care re-
quirements, and mortality.
Outcomes of Interest
Specific outcomes of interest were defined as follows failure
of initial agent, defined as lack of clinical improvement after
5 days or change in treatment regimen because of lack of
clinical response; relapse, defined as any recurrence of CDI
within a 90-day period after initial presentation; and death
within 90 days of presentation (all-cause mortality). The
institutional review boards of the University of Michigan
Health System approved this study.
Data Analysis
Univariate analysis using t-tests for continuous variables
and the chi-square or Fisher exact test for categorical
variables identified risk factors for treatment failure, re-
lapse, and death in patients with CDI. A two-tailed P.05
was considered statistically significant. Crude odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated
for categorical variables. Crude ORs for continuous vari-
ables were obtained using simple logistic regression. Vari-
ables that were significant to P 5.20 and variables that had
a priori clinical significance were then analyzed using
multivariate logistic regression modeling. All statistical
analysis was performed using SAS 9.1 (SAS Institute, Inc.,
Cary, NC).
RESULTS
Seventy patient aged 80 and older were identified with CDI
(mean age 84.0  4.1, range 80–94). Twenty-nine (41.1%)
were male. Common medical comorbidities were coronary
artery disease (35.7%), renal insufficiency (27.1%), and
diabetes mellitus (18.5%). The mean peak white blood cell
(WBC) count was 14.8  8.6 thousand/mm3 (range 3.6–
46.4). Fifty-seven (81.4%) patients received antibiotics, and
41 (58.5%) received proton pump inhibitors during the 30
days before presentation (Table 1).
Initial therapy for CDI consisted of metronidazole in 65
(92.8%), and vancomycin in two (2.9%). Three patients
did not receive antimicrobial therapy for CDI treatment.
Complications associated with CDI included toxic mega-
colon in three patients (4.3%), two of whom required
colectomy.
Treatment failure prompting a change in CDI therapy
occurred in 18 of 65 patients (27.7%), all of whom received
initial treatment with metronidazole. All 18 were switched
to oral vancomycin. These 18 patients received a median of
7 days of metronidazole before the switch to vancomycin.
All 18 had appropriate dosing of metronidazole, generally
500 mg three or four times a day.
Twelve patients (17.1%) experienced disease relapse
within 90 days after completion of treatment for CDI. All
12 received initial treatment with metronidazole: four with
relapsed disease had experienced treatment failure during
their initial presentation, prompting a switch to oral van-
comycin.
Twelve patients (17.1%) died within 90 days of initial
presentation and diagnosis; one death was directly attrib-
utable to CDI. These deaths occurred from 2 to 85 days
after the initial diagnosis of CDI (median 33.5 days). Over-
all, six deaths occurred within 30 days of presentation
(8.6%). Neither treatment failure nor disease relapse ap-
peared to be associated with a higher death rate when
compared with each other. The death rate for patients ex-
periencing treatment failure was 11.1%; for patients with
CDI relapse, it was 8.3%.
Of the 70 patients studied, 31 required 40 admissions
with a primary admitting diagnosis of CDI, 15 were treated
as outpatients, and 24 developed CDI during hospitalization
for another medical or surgical issue. Of the 31 patients ad-
mitted for CDI, 25 were community dwelling and indepen-
dent with activities of daily living before admission; eight of
these 25 (32.0%) required discharge to subacute settings be-
cause of impaired mobility and functional decline.
Overall, treatment failure occurred in 18 (25.7%) pa-
tients. Of the 31 patients admitted primarily for CDI, 11
(35.5%) experienced treatment failure. Fifteen patients
were treated on an outpatient basis, with three treatment
failures (20%). Of the 24 patients who developed CDI dur-
ing an admission for another reason, four experienced
treatment failure (16.6%). Although the patients admitted
with a primary diagnosis of CDI had a higher rate of treat-
ment failure, this difference did not achieve statistical sig-
nificance (OR 5 2.5, 95% CI 5 0.84–7.6, P 5.16).
Univariate analysis identified risk factors associated
with outcomes of interest (Table 2). Patients experiencing
Table 1. Characteristics for Patients Aged 80 and Older
with Clostridium Difficile–Associated Diarrhea (N 5 70)
Characteristic Value
Age, mean  SE 84.0  4.1
Male, n (%) 29 (41.1)
Coronary artery disease, n (%) 25 (35.7)
Congestive heart failure, n (%) 22 (31.4)
Diabetes mellitus, n (%) 13 (18.5)
Renal insufficiency (creatinine clearanceo30 mL/min) , n (%) 19 (27.1)
Colon cancer, n (%) 2 (2.8)
Inflammatory bowel disease, n (%) 2 (2.8)
Peak white blood cell count, K/mm3, mean  SE 14.8  8.6
Surgery during previous month, n (%) 11 (15.7)
Antimicrobial use in past 30 days, n (%) 57 (81.4)
Proton pump Inhibitor in past 30 days, n (%) 41 (58.5)




Toxic megacolon 3 (4.3)
Need for colectomy 2 (2.9)
Relapse 12 (17.1)
Treatment failure 18 (25.7)
Death (within 90 days) 12 (17.1)
Three patients did not receive antimicrobial therapy for Clostridium
difficile–associated diarrhea.
SE 5 standard error.
660 COBER AND MALANI APRIL 2009–VOL. 57, NO. 4 JAGS
treatment failure had a higher peak WBC count than those
who responded to initial therapy (Po.01). Coronary artery
disease was highly associated with 90-day mortality (crude
OR 5 4.4, P 5.05). These risk factors remained indepen-
dently associated with treatment failure and 90-day mor-
tality on multivariate analysis (Table 3).
DISCUSSION
CDI is a serious illness associated with significant morbidity
and mortality. In recent years, the incidence of CDI infec-
tion has more than doubled.4 Past investigations have noted
that older adults who develop CDI are at high risk of serious
adverse effects, including death. It was desired to describe
the clinical course of patients aged 80 and older, including
identification of possible risk factors for poor outcomes and
treatment failure.
These findings suggest that, in the ‘‘oldest’’ elderly pa-
tients with CDI, treatment failure on metronidazole oc-
curred frequently (27.7%) and appears to be associated
with higher peak WBC count (P 5.01). The relationship
between high WBC count and greater severity of clinical
disease is well described; this association was also observed
in the initial reports of B1/NAP1 strain outbreaks.2,6 The
nearly 28% rate of metronidazole failure observed in this
cohort is consistent with the rate of treatment failure in
patients with severe CDI described in two recent prospec-
tive studies of CDI treatment.7,8
Of previously community-dwelling patients admitted
with a primary diagnosis of CDI, 32.0% were discharged to
subacute care. Overall death rates were significant, with
17.1% dying within 90 days of CDI diagnosis and one
death directly attributable to CDI. If only hospitalized pa-
tients are considered (n 5 55), the death rate climbs to
21.8%. Adjusted odds of death in patients with coronary
artery disease were more than five times as high as patients
without coronary artery disease, (P 5.02).
Limitations of this study include the retrospective de-
sign and the small sample size. The overwhelming use of
metronidazole as the first line of therapy in these patients
makes it impossible to compare the efficacy of metronidaz-

















































































































































































































































































































































































































































































































































































































































































































































Table 3. Multivariate Analysis of the Association
Between Patient Characteristics, Treatment Failure,
and 90-Day Mortality in Patients with Clostridium
Difficile–Associated Diarrhea




White blood cell count 1.1 (1.0–1.2) .007 1.1 (1.0–1.2) .02
90-day mortality
Coronary artery disease 4.4 (1.2–16.7) .05 5.5 (1.3–23) .02
White blood cell count 1.0 (0.9–1.1) .35 1.1 (1.0–1.2) .13
Based on a multivariable logistic regression adjusting for age, renal insuffi-
ciency, serum albumin, coronary artery disease, congestive heart failure, di-
abetes mellitus.
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the 27.7% rate of treatment failure in patients receiving
metronidazole is notable and suggests that metronidazole
may not be the appropriate initial agent in older adults,
particularly those with high WBC counts on presentation or
other signs and symptoms of severe CDI. The question of
optimal therapy for CDI remains unclear, although it is
evolving. Many experts have recommended vancomycin as
first-line therapy in older adults, especially for patients with
severe disease, characterized by high WBC count, severe
abdominal pain, or rising creatinine.7,9–11 Several clinical
studies have demonstrated that oral vancomycin provides
higher rates of cure than metronidazole in patients with
severe CDI,7,8 although drug costs remain a major barrier
for use of vancomycin as a first line of therapy, particularly
in mild or moderate disease, where there is no evidence that
vancomycin is superior to treatment with metronidazole.12
As the burden of CDI in older adults continues to grow,
so does the need to improve understanding of disease in this
population. Larger prospective studies are needed to deter-
mine risk factors for CDI treatment failure, relapse, and
poor outcomes in order to develop better paradigms for
CDI treatment for older adults, including how to identify
patients who should receive initial therapy with oral van-
comycin and patients who may benefit from extended
treatment courses or tapered therapy. Efforts to prevent
CDI through directed infection control measures and pru-
dent use of antimicrobials remain critical, particularly in
the long-term and subacute care settings. Finally, the prob-
lem of functional decline associated with the diagnosis of
CDI deserves consideration. Although pre- and post-
admission functional ability was not formally assessed, a
sizable number of patients previously independent in ac-
tivities of daily living admitted specifically for CDI required
subacute care after discharge.
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